Testing a new treatment for Alzheimer's disease
Official title: Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
Funded at Auburn University at Auburn · NIH-10985011 · Data updated 2026-11-12
This study is testing a new treatment called AU403 for Alzheimer's disease to see if it can help improve symptoms or slow down the disease, and it's designed for people living with Alzheimer's who are looking for new options.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Auburn University at Auburn NIH-funded |
| Lab location | 1 site (Auburn, UNITED STATES) |
| Project start | March 1, 2023 |
| Project end | February 28, 2027 |
| Funding year | 2025 |
| Award (this year) | $311,965 |
| NIH project number | 4R33NS126618-02 |
| Project ID | NIH-10985011 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or related dementias.
✕Less likely to help
Patients with other forms of dementia not related to Alzheimer's may not receive benefit from this research.
What this research studies
This research investigates a novel treatment for Alzheimer's disease using a specific compound called AU403, which targets certain receptors in the body to potentially reduce harmful effects associated with the disease. The study will assess how well AU403 works in the body, including its absorption and safety, through a series of laboratory tests and experiments. Patients may benefit from this research as it aims to develop a new therapy that could improve symptoms or slow the progression of Alzheimer's disease.
Why it matters
Potential benefit: If successful, this research could lead to a new effective treatment option for patients with Alzheimer's disease.
How similar studies have gone: Other research has shown promise in targeting similar receptors for Alzheimer's treatment, suggesting potential for success with this approach.
Where this research is happening
-
Auburn University at Auburn
Auburn, United States Active
Researchers
- Principal investigator: Amin, Rajesh H — Auburn University at Auburn
- Study coordinator: Amin, Rajesh H
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.